Related Experiment Videos
The remittive effects of alefacept
1Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA. krueger@derm.med.utah.edu
Journal of Cutaneous Medicine and Surgery
|January 26, 2005
Summary
Alefacept therapy offers a sustained response for chronic plaque psoriasis patients, with median durations of 7 to 10 months. This indicates alefacept acts as a remittive treatment for psoriasis.
Area of Science:
- Immunology
- Dermatology
- Clinical Pharmacology
Background:
- Chronic plaque psoriasis is a significant autoimmune skin condition.
- Alefacept is an immunomodulatory biologic agent used for psoriasis treatment.
- Understanding treatment duration is crucial for managing chronic diseases.
Purpose of the Study:
- To assess the duration of response to alefacept in patients with moderate to severe chronic plaque psoriasis.
- To analyze response duration based on different efficacy endpoints and patient subsets.
Main Methods:
- Retrospective analysis of Phase 2 and Phase 3 clinical trial data.
- Duration of response assessed by time to retreatment (Phase 2) and maintenance of Psoriasis Area and Severity Index 50 (PASI 50) (Phase 3).
- Analysis of patient subsets achieving PASI 75 or Physician Global Assessment 'clear'/'almost clear'.
Main Results:
- Median duration of response ranged from 7 to 10 months across studies.
- Consistent response durations were observed regardless of alefacept administration route (IV or IM).
- Patients achieving higher response levels (PASI 75) also experienced sustained remissions.
Conclusions:
- Alefacept demonstrates a remittive effect in chronic plaque psoriasis.
- The duration of response suggests a clinically meaningful benefit for patients.
- Alefacept provides a sustained therapeutic option for moderate to severe psoriasis.